BMS To Launch Novel Schizophrenia Therapy Cobenfy Within The Next Month
KarXT Came From $14bn Karuna Buy
BMS said Cobenfy’s annual list price of $22,500 is in line with other branded antipsychotics and sees the drug as a 2025 launch given late 2024 approval and ongoing reimbursement talks.
